EP0703917A1 - Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c - Google Patents

Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Info

Publication number
EP0703917A1
EP0703917A1 EP94918859A EP94918859A EP0703917A1 EP 0703917 A1 EP0703917 A1 EP 0703917A1 EP 94918859 A EP94918859 A EP 94918859A EP 94918859 A EP94918859 A EP 94918859A EP 0703917 A1 EP0703917 A1 EP 0703917A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
proteinkinase
longisporoflavus
streptomvces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94918859A
Other languages
German (de)
English (en)
Inventor
Pascale Hoehn-Thierry
Oreste Ghisalba
Heinrich Peter
Théophile Moerker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Priority to EP94918859A priority Critical patent/EP0703917A1/fr
Publication of EP0703917A1 publication Critical patent/EP0703917A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Definitions

  • the invention relates to a novel secondary metabolite obtainable from a mutant strain of Streptomvces longisporoflavus having the formula
  • salts of compound (I) or (II) are, for example, salts with suitable mineral acids, such as hydrohalic acids, sulfuric acid or phosphoric acids, e.g., hydrochlorides, hydrobromides, sulfates, hydrogen sulfates or phosphates, salts with suitable aliphatic or aromatic sulfonic acids or N-substituted sulfamic acids, e.g.
  • methanesulfonates benzenesulfonates, p-toluenesulfonates or N-cyclohexylsulfamates (cyclamates), or salts with strong organic carboxylic acids, such as lower alkanecarboxylic acids or optionally unsaturated or hydroxylated aliphatic dicarboxylic acids, e.g. acetates, oxalates, malonates, maleates, fumarates, malates, tatrates or citronates.
  • strong organic carboxylic acids such as lower alkanecarboxylic acids or optionally unsaturated or hydroxylated aliphatic dicarboxylic acids, e.g. acetates, oxalates, malonates, maleates, fumarates, malates, tatrates or citronates.
  • the invention further relates to a process for the production of the compound of the formula (I), which process comprises cultivating Streptomvces longisporoflavus mutant strain M14 (DSM 8325) in a suitable nutrient medium and isolating said compound.
  • the process comprises cultivating Streptomvces longisporoflavus mutant M14 (DSM 8325) in a culture medium containing assimilable sources of carbon, sources of nitrogen and mineral salts, separating the cells from the culture broth and extracting it with an organic water-immiscible solvent, separating the organic phase from the aqueous phase, concentrating the organic phase by evaporation and purifying the resulting crude compound of the formula (I) by means of chromatography and/or crystallization from the same or a different organic water-immiscible solvent.
  • aqueous solution or suspension which contains suitable sources of carbon and nitrogen as well as mineral salts.
  • suitable sources of carbon and nitrogen are complex organic substances, such as proteins and protein hydrolysates, typically casein, peptone, meat extract, yeast extract, cotton seed, soybean meal, peanut meal, sun-flower seed derived protein nutrient, etc.
  • suitable mineral salts typically include chlorides, carbonates, sulfates and phosphates of alkali metals and alkaline earth metals, for example sodium, potassium, calcium and magnesium, and also commercially available trace element mixtures. It is also advantageous to add further growth-promoting substances, especially vitamins, conveniently in the form of commercially available standard vitamin solutions.
  • Cultivation is carried out aerobically, i.e. conveniently in surface cultures, or preferably submerged with shaking or stirring while introducing air or oxygen into the shaking flask or fermenter. Cultivation is preferably carried out in the neutral pH range, i.e. at about pH 5-8, preferably at pH 6-7, and in the temperature range from about 25-30°C, preferably at about 28°C.
  • the cultivation time is preferably from 3 to 5 days.
  • the biomass is separated from the culture broth when cultivation is complete, and extracted with an organic water-immiscible solvent.
  • Suitable organic solvents include esters of aliphatic acids, typically lower alkyl esters, such as methyl or ethyl esters, of lower alkanoic acids such as acetic acid, and halogenated hydrocarbons, e.g. methylene chloride or chloroform. Extraction of the aqueous culture broth can be done twice or three times. After concentrating the combined extracts by evaporation, the residue is further purified by chromatographic means, e.g. by means of column chromatography (such as HPLC or flash chromatography) or TLC. Alternatively or additionally, the product may be crystallized from an organic water-immiscible solvent such as one of those detailed above.
  • the compound of the formula (I) can be conveniently crystallized e.g. from ethyl acetate.
  • the novel compound has valuable, especially pharmacologically valuable, properties and can be used for the prevention and treatment of diseases in a mammal, such as a human or an animal.
  • the compound of the formula (I) is a selective inhibitor of isotypes of the enzyme proteinkinase C. While staurosporine of the formula (II) shows no significant differences in the inhibition of isotypes of the enzyme proteinkinase C, the compound of the formula (I) most selectively and preferentially inhibits isotypes alpha, beta-2 and gamma whilst, e.g., isotypes beta-1 and eta are inhibited to a much lower degree (by a factor of 5-10).
  • Isotypes alpha, beta-2 and gamma of proteinkinase C are inhibited by the compound of the formula (I) already at a concentration (IC 50 ) of approximately 0.04 ⁇ mol/liter.
  • the compound of the formula (I) inhibits other enzymes, for example proteinkinase A, protein-phosphorylase-kinase and protein-tyrosin-kinase, only at much higher concentrations. This demonstrates the surprising selectivity of the compound of the formula (I).
  • the compound of the formula I has antiproliferative properties which can be demonstrated by the inhibitory action on the growth of human T24 bladder carcinoma cells.
  • the compound of the formula (I) can be used, in particular, for the prophylaxis or treatment of diseases which respond to proteinkinase C inhibition. It can also be used as an antitumor active ingredient, for example for the therapy of tumors of the bladder.
  • the novel compound can be used furthermore for the treatment of multidrug resistant tumors, in particular P-glycoprotein mediated resistance, and shows synergistic effects when combined with other antitumor active compounds, particularly all those showing cross-resistance in MDR (multidrug resistance) like doxorubicin, daunorubicin, vincristine, vinblastine, etoposide, taxol, mitomycin C, actinomycin D or mitoxantrone.
  • MDR multidrug resistance
  • the compound of the formula (I) is a potent inhibitor of the osteoclast proton pump (OPP).
  • Osteoclasts are a class of bone cells responsible for bone resorption which, during normal bone remodeling, is followed faithfully by osteoblastic bone formation. Osteopenia results from an imbalance of the opposing activities of osteoclasts and osteoblasts such that the rate of bone resorption exceeds the rate of accretion. Osteoclasts resorb bone by secreting protons and lysosomal enzymes into a sealed extracellular lacuna beneath the cell. The resulting low pH demineralizes the bone and activates the secreted lysosomal enzymes which then digest the exposed organic collagen matrix.
  • OPP osteoclast proton pump
  • the protons are pumped out of the osteoclasts by an ATP-dependent H + -pump (H + -ATPase proton pump, osteoclast proton pump) located in the ruffled border membrane of the cell bordering the extracellular lacuna. Inhibition of proton secretion would offer a way to control bone loss.
  • the osteoclast proton pump appears to be a member of the multimeric vacuolar class of H + -ATPase enzymes present in the membrane of a variety of intracellular vacuoles (e.g. clathrin-coated vesicles, chromaffin granules, lysosomes).
  • the compound according to the invention is an extremely potent inhibitor of H + - ATPase proton pump isolated from clathrin-coated vesicles from bovine brain.
  • the inhibitory concentration (IC 50 ) is approximately 0.0006 ⁇ M.
  • the compound according to the invention can be used for the prevention or treatment of the elevated bone loss characteristic of a variety of pathological conditions such as primary osteoporosis (juvenile, idiopathic, congenital, postmenopausal, involutional) and secondary osteopenia associated with maUgnancy, renal insufficiency, endocrinopathies, malabsorption syndromes, hepatic disease, immobilization, arthropathies and iatrogenic causes.
  • pathological conditions such as primary osteoporosis (juvenile, idiopathic, congenital, postmenopausal, involutional) and secondary osteopenia associated with maUgnancy, renal insufficiency, endocrinopathies, malabsorption syndromes, hepatic disease, immobilization, arthropathies and iatrogenic causes.
  • the inventive compound can be used in a method for protecting nerve cells of mammal from degeneration induced by excitatory amino acids. Examples are Alzheimer's disease, moto neuron disease, Parkinson's disease, cerebrovascular disease, AIDS dementia, epilepsy, Huntington's disease and concussive or penetrating injuries to the brain or spinal cord.
  • the inventive compound can be administered in combination with a neurotrophic factor, preferably a member of the neurotrophic family, and most preferably nerve growth factor (NGF).
  • a neurotrophic factor preferably a member of the neurotrophic family, and most preferably nerve growth factor (NGF).
  • the invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the active ingredient, in particular an amount which is effective for the prophylaxis or therapy of one of the above-mentioned diseases, together with pharmaceutically acceptable carriers which are suitable for topical, for example in the treatment of skin tumors, enteral, for example oral or rectal, or parenteral (for example i.v., s.c. or transdermal) administration, and which can be inorganic or organic, solid or liquid.
  • pharmaceutically acceptable carriers which are suitable for topical, for example in the treatment of skin tumors, enteral, for example oral or rectal, or parenteral (for example i.v., s.c. or transdermal) administration, and which can be inorganic or organic, solid or liquid.
  • compositions which are used for oral administration are, in particular, tablets or gelatine capsules which comprise the active ingredient together with diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerol, and/or lubricants, for example silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • diluents for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerol
  • lubricants for example silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Tablets can also comprise binders, for example magnesium aluminum silicate, starches such as maize, wheat or rice starch, gelatine, methylcellulose, sodium carboxylmethylcellulose and/or polyvinylpyrrolidone and, if desired, disintegrants, for example starches, agar, algic acid or a salt thereof such as sodium alginate, and/or effervescent mixtures, or adsorbants, colorants, flavourings and sweeteners.
  • binders for example magnesium aluminum silicate, starches such as maize, wheat or rice starch, gelatine, methylcellulose, sodium carboxylmethylcellulose and/or polyvinylpyrrolidone and, if desired, disintegrants, for example starches, agar, algic acid or a salt thereof such as sodium alginate, and/or effervescent mixtures, or adsorbants, colorants, flavourings and sweeteners.
  • the pharmacologically active compound of the present invention can furthermore be used in
  • Such solutions are preferably isotonic aqueous solutions or suspensions, it being possible for those to be prepared prior to use, for example in the case of lyophilized compositions which comprise the pure active ingredient or the active ingredient together with a carrier, for example mannitol.
  • the pharmaceutical compositions can be sterilized and/or comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers.
  • compositions which, if desired, can comprise further pharmacologically active substances, are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilization processes and comprise from approximately 0.01 % to 90 %, in the case of lyophilizates up to 100 %, in particular from approximately 0.1 % to approximately 50 %, of the active ingredient, a concentration of active ingredient of below 1 % being particularly suitable for compositions for topical administration.
  • the invention also relates to the use of the compound of the formula I, preferably in the form of pharmaceutical compositions, for the prophylaxis or the therapeutic treatment of the human or animal body, in particular in the case of the above-mentioned diseases.
  • the invention especially relates to a method for inhibiting proteinkinase C, especially the above-mentioned isotypes thereof, in a warm-blooded species requiring such a treatment, whereby an effective proteinkinase C-inhibiting dose of the compound of the formula I is administered to this representative of a warm-blooded species.
  • the invention likewise especially relates to a method for inhibiting osteoclast proton pump in a warm-blooded species requiring such a treatment, whereby an effective osteoclast proton pump-inhibiting dose of the compound of the formula I is administered to such warm-blooded species.
  • the dose of the active ingredient depends, inter alia, on the type and severity of the disease, the nature and size of the species to be treated, the age and condition of the species, the response to treatment and the way in which the active ingredient is administered.
  • a representative of a warm-blooded species having a body weight of approximately 70 kg is administered a daily dose of 1 mg to 1500 mg, preferably 10 mg to 500 mg, of the compound of the formula I.
  • This total daily dose is preferably split into 1-3 daily administrations.
  • the dose in the case of oral administration is approximately two to three times higher than in the case of parenteral administration, i.e. rather in the upper range of the above-mentioned doses.
  • novel compound of the formula (I) is furthermore a valuable intermediate for the production of other pharmaceutically active compounds such as compounds inhibiting subtypes of proteinkinase C or osteoclast proton pump.
  • novel strain Streptomvces longisporoflavus M14 DSM 8325 is a further embodiment of the present invention.
  • the examples which follow illustrate the invention without any restriction whatsoever.
  • soluble starch 20 g/1 yeast extract 4 g/1 agar 20 g/1 pH before sterilization: about 7
  • the cultures exhibited a white to grey color on the surface of the mycelium.
  • a sterile Tween 80 solution (0.5%) was added to each plate. Spores were removed by scraping the surface of these plates with an inoculating loop by gentle pressure. The spore suspension obtained was then transferred to a glass Petri dish. The spore concentration is controlled and determined with a microscope. The suspension was irradiated under the UV lamp with constant agitation: 500m W/cm 2 during 50". The irradiated spore suspension was then diluted by factor 100 to 1000, left for 1 day at room temperature in the dark, and then plated out on complete medium plates (sporulation agar SPA). The plates were left incubated at 28°C in the dark for 5 days and then they were replica-plated to "minimal medium” (MM)
  • mutant M 14 One colony appeared to have a poor and thin development on both minimal media but a normal development on the complete medium (so-called ghost colony) and was designated mutant M 14.
  • the fermentation is started using 2 inoculum stages.
  • Media used for the preculture and fermentation are the following ones:
  • fermentation medium NL 3 (antifoam SAG 471 is added only if necessary), see above.
  • the temperature used is about 28°C.
  • the inoculum stages are performed at a pH from about 7.6, whereas the fermentation is performed at a pH from about 6.0 to 7.0. a. First Preculture
  • Cryo-tubes, slants or agar plates are used to inoculate Erlenmeyer flasks containing the medium NL148a. The flask is left to incubate at 28°C for 48 hours at 220 rpm.
  • One milliliter of fresh culture is used to inoculate 100 ml of medium NL 148a in 500 ml Erlenmeyer flasks with 1 baffle (1% inoculum). The flasks are left to incubate at 28°C for 48 hours at 250 rpm.
  • IR (KBr): 3420, 3252, 3049, 2930, 1660, 1587, 1458, 1420, 1398, 1348, 1317, 1283, 1250, 1227, 1173, 1151, 1126, 1101, 1070, 1045, 1020, 955, 922, 851, 822, 789, 773, 744, 663, 631 cm "1 (the most prominent absorption bands are underlined).
  • the fermentation broths obtained from different fermenter cultures are combined to yield 77 1.
  • the whole broth is extracted by vigorous stirring with twice the volume of ethyl acetate.
  • the filter cake is washed with an additional volume of 301 of ethyl acetate.
  • the combined organic phases are separated, concentrated and evaporated to dryness.
  • the crude extract is triturated with 11 of n-heptane. The evaporation of the heptane phase gives a residue of a thin oil, which according to TLC analysis is completely devoid of staurosporine related compounds.
  • the heptane-insoluble residue is dissolved in dichloromethane which leads to a spontaneous crystallization of a first crop of crystals.
  • the raw crystallizate is dissolved in methanol, treated with active carbon and filtered. The clear filtrate is concentrated and recrystallized from ethyl acetate.
  • the mother liquor and the previously obtained solution in dichloromethane are combined and chromatographed on a 1 1 column with silicagel Si 60 (Merck, particle size 15-25 ⁇ m).
  • the fractions containing the desired product are eluted with a solvent mixture consisting of 95 % dichloromethane and 5 % methanol, combined and evaporated to dryness. Rechromatography of these fractions using the same method leads to semipure material. Recrystallization from ethyl acetate yields a second crop of pure substance.
  • the mother liquors are further purified by a repeated chromatography and recrystallization cycle which produces a third crop of pure substance.
  • Tablets comprising 50 mg of active ingredient are prepared in the customary manner in the following composition:
  • the active ingredient is mixed with some of the wheat starch, the lactose and colloidal silica, and the mixture is passed through a sieve.
  • Some more wheat starch is made into a paste with 5 times the amount of water in a water bath, and the powder mixture is kneaded with this paste until a slightly kneadable composition has been formed.
  • the kneadable composition is pressed through a sieve of mesh size approx. 3 mm and dried, and the dry granules obtained are passed again through a sieve.
  • the remainder of the wheat starch, the talc and the magnesium stearate are thereinafter admixed, and the mixture is compressed to give 1000 notched tablets of 357 mg weight each containing 50 mg of active ingredient.
  • the strain Streptomvces longisporoflavus M14 was deposited on May 27, 1993 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM) (German Collection of Microorganisms and Cell Cultures) in Braunschweig, FRG, under No. DSM 8325.
  • DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un nouveau métabolite secondaire répondant à la formule (I) a été isolé d'une souche mutante de Streptomyces longisporoflavus. Ce composé présente des caractéristiques pharmaceutiques avantageuses, notamment comme inhibiteur de protéine-kinase C.
EP94918859A 1993-06-17 1994-06-09 Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c Ceased EP0703917A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP94918859A EP0703917A1 (fr) 1993-06-17 1994-06-09 Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP93810437 1993-06-17
EP93810437 1993-06-17
PCT/EP1994/001883 WO1995000520A1 (fr) 1993-06-17 1994-06-09 Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c
EP94918859A EP0703917A1 (fr) 1993-06-17 1994-06-09 Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Publications (1)

Publication Number Publication Date
EP0703917A1 true EP0703917A1 (fr) 1996-04-03

Family

ID=8214987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94918859A Ceased EP0703917A1 (fr) 1993-06-17 1994-06-09 Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Country Status (4)

Country Link
EP (1) EP0703917A1 (fr)
JP (1) JPH08511785A (fr)
AU (1) AU7000094A (fr)
WO (1) WO1995000520A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
JPH10500394A (ja) * 1994-06-01 1998-01-13 チバ−ガイギー アクチェンゲゼルシャフト 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするための多環式ラクタム誘導体
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
AU2565795A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Carbazole derivatives as agents against multi-drug resistance
JPH11509193A (ja) * 1995-06-27 1999-08-17 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン 細胞傷害を増強するための細胞周期動力学の動的遅延方法
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6210935B1 (en) 1995-08-30 2001-04-03 Novartis Ag Staurosporin biosynthesis gene clusters
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
DE69715862T2 (de) 1996-06-25 2003-04-10 Cephalon, Inc. Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
AU4250697A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
PL331761A1 (en) * 1996-08-30 1999-08-02 Lilly Co Eli Application of pkc inhibitors in production of a drug for treating central nervous system diseases associated with hiv infections
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
CN104593281A (zh) * 2013-10-31 2015-05-06 王林 几个具有强杀虫活性的吲哚咔唑生物碱及产生菌株
CN107603922B (zh) * 2017-11-06 2019-10-18 海南大学 海绵共生链霉菌及其发酵生产星形孢菌素的方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2766360B2 (ja) * 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
WO1991009034A1 (fr) * 1989-12-14 1991-06-27 Schering Corporation Indolocarbazols provenant de saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951, atcc 53856

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9500520A1 *

Also Published As

Publication number Publication date
AU7000094A (en) 1995-01-17
JPH08511785A (ja) 1996-12-10
WO1995000520A1 (fr) 1995-01-05

Similar Documents

Publication Publication Date Title
EP0703917A1 (fr) Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c
EP0351865B1 (fr) Composés DC-89 et procédé pour leur préparation
JP2817064B2 (ja) Ｂｕ―３６０８抗生物質のセリン類縁体
NO300812B1 (no) Fremgangsmåte for fremstilling av antitumorsubstans BE-13793C, samt biologisk ren kultur istand til å frembringe denne
HOEHN et al. 3'-Demethoxy-3'-hydroxystaurosporine, a novel staurosporine analogue produced by a blocked mutant
EP0106341B1 (fr) Substance physiologiquement active p-23924, sa préparation et emploi
EP0735141A2 (fr) Procédé de préparation de benzo(b)thiophène glucuronides
KR840001258B1 (ko) 신항생물질 mf 266 물질의 제조방법
US5861518A (en) Phthalide compounds and their production process
EP0139458B1 (fr) Composé antibiotique et sa préparation
US6297043B1 (en) Mumbaistatin, a process for it's production and its use as a pharmaceutical
JP3119680B2 (ja) 新規抗生物質バルヒマイシン、その製造方法およびそれを含有する抗菌剤
KR950013857B1 (ko) 신규 항생물질 무레이도마이신 a, b, c 및 d 그의 제조 방법 및 치료학적 용도
US5079376A (en) Novel substance uct-1003 and process for producing the same
EP0818464B1 (fr) Methylsulfomycin 1, procédé de sa préparation et utilisation
EP0659752B1 (fr) Substance antibacterienne e anti-tumorale, la dc 114-a1
AU702777B2 (en) UCK14 compounds
US5334613A (en) Antibacterial substance BE-24566B
EP0657412B1 (fr) Derive de saintopine
EP1474440B1 (fr) Coniosulfures et derives, leurs procedes de production et leur utilisation en tant que medicaments
KR970001001B1 (ko) I-디옥시만노딜리마이신의 제법
US4146536A (en) Nocardicin E and F, and process for production thereof
JP2750239B2 (ja) アデノホスチンａまたはｂならびにその製法
CA2008628C (fr) Substance uct-1003 et procede de production
JPH0788364B2 (ja) 新規物質アロサミゾリン

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

17Q First examination report despatched

Effective date: 19970402

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19981010